Fannie Mae, Freddie Mac shares tumble after conservatorship comments
AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) disclosed on Friday that its Chief Executive Officer, Pascal Soriot, was awarded 8,970 ordinary shares on May 21, 2025, as part of the company’s long-term incentive plan. This award was the result of a performance share plan (AZPSP) established in 2020 and was subject to a three-year performance period followed by a two-year holding period.
The performance conditions attached to the original grant led to 97% of the potential shares vesting, with the remainder lapsing. The shares were distributed under the AZPSP, which had been modified following shareholder approval at the company’s 2020 Annual General Meeting.
As a result of the vesting and after accounting for dividend reinvestment and tax obligations, Soriot’s stake in the company has changed. The fair market value of the shares at vesting was determined to be 10,418 pence each, based on the closing price of AstraZeneca (NASDAQ:AZN)’s shares on the last trading day before the vesting date.
The transaction was conducted outside a trading venue, and the shares were acquired for nil consideration, meaning no payment was required for the transfer of shares. This event was reported in compliance with the EU Market Abuse Regulation, which is part of UK law following the European Union (Withdrawal) Act 2018.
AstraZeneca, headquartered in Cambridge, UK, is a global biopharmaceutical company engaged in the development of prescription medicines across various therapeutic areas. The information regarding this shareholding update is based on the latest 6-K filing by AstraZeneca with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.